Find Erlotinib Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Erlotinib Hydrochloride

Erlotinib Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

54 API Suppliers, 28 USDMF, 1 JDMF, 16 EU WC, 14 KDMF, 16 NDC API, 29 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

3 Suppliers

3 Suppliers

DOSSIERs // Finished Dosage Formulations

66 Dossiers, 36 FDA Orange Book, 3 Europe, 14 Canada, 9 South Africa, 4 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 100MG BASE
TABLET;ORAL - EQ 150MG BASE
TABLET;ORAL - EQ 25MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 29 Kerry, 11 Roquette, 10 Corel Pharma Chem, 10 Microlex e.U, 10 Sigachi Industries, 8 Gangwal Healthcare, 6 Seppic, 6 Lonza Capsugel, 5 BASF, 5 DFE Pharma, 5 Ideal Cures Pvt Ltd, 5 Gangwal Chemicals, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Vasa Pharmachem, 3 Kima Chemical, 3 Prachin Chemical, 2 The Dow Chemical Company, 2 Pharmatrans-Sanaq, 1 Nanjing Well Pharmaceutical, 1 SPI Pharma, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 1 ACG Worldwide, 1 Ingredion Pharma Solutions

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives, 39 Fillers, Diluents & Binders, 21 Controlled & Modified Release, 18 Direct Compression, 16 Disintegrants & Superdisintegrants, 13 Granulation, 12 Lubricants & Glidants, 11 Thickeners and Stabilizers, 9 Co-Processed Excipients, 7 Film Formers & Plasticizers, 6 Taste Masking, 5 Empty Capsules, 4 Vegetarian Capsules, 3 Chewable & Orodispersible Aids, 3 API Stability Enhancers, 2 Emulsifying Agents, 2 Rheology Modifiers, 2 Coloring Agents, 1 Topical, 1 Parenteral, 1 Solubilizers

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 3 Finished Drug Prices

MARKET PLACE

3 APIs, 1 DOSSIERS // FDF

ANALYTICAL SOLUTION(s)

1 Other Ref. Standards

1 Other Ref. Standards

DIGITAL CONTENT

12 News

12 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

3,684

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

51.00

Annual Reports

FDF Market Place

EXCIPIENTS

136

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 183319-69-9, Erlotinib hcl, Tarceva, Osi-774, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride, Osi 774

Molecular Formula

C₂₂H₂₄ClN₃O₄

Molecular Weight

429.9 g/mol

InChI Key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

FDA UNII

DA87705X9K

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

1 2D Structure

Erlotinib Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride

2.1.2 InChI

InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

2.1.3 InChI Key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl

2.2 Other Identifiers

2.2.1 UNII

DA87705X9K

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 11c Erlotinib

2. 11c-erlotinib

3. 358,774, Cp

4. 358774, Cp

5. Cp 358,774

6. Cp 358774

7. Cp-358,774

8. Cp-358774

9. Cp358,774

10. Cp358774

11. Erlotinib

12. Erlotinib Hcl

13. Hcl, Erlotinib

14. Hydrochloride, Erlotinib

15. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

16. Osi 774

17. Osi-774

18. Osi774

19. Tarceva

2.3.2 Depositor-Supplied Synonyms

1. 183319-69-9

2. Erlotinib Hcl

3. Tarceva

4. Osi-774

5. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Hydrochloride

6. Osi 774

7. Erlotinib (hydrochloride)

8. Cp-358774

9. Cp 358774

10. Erlotinib, Hydrochloride Salt

11. Tarceva (erlotinib Hydrochloride)

12. Nsc 718781

13. Cp-358,774-01

14. Da87705x9k

15. 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride

16. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride

17. Cp-358

18. 4-quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, Hydrochloride (1:1)

19. Nsc-718781

20. 6,7-bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hcl

21. 183319-69-9 (hcl)

22. 4-(m-ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline Monohydrochloride

23. Cp-358774-01

24. 4-quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, Monohydrochloride

25. [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine Hydrochloride

26. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride.

27. Chebi:53509

28. Osi-744

29. Smr002529980

30. Erlotinib Hydrochloride [usan]

31. Nsc718781

32. 183319-69-9 Pound Not183321-74-6

33. Erlotinib Hcl (osi-744)

34. Unii-da87705x9k

35. Erlotinib, Hcl

36. Erlotinib Hcl Salt

37. Erlotinib Hydrochloride [usan:inn]

38. Tarceva (osi)

39. Tarceva Hydrochloride

40. Mfcd07781272

41. Erlotonib Hydrochloride

42. Erlotinib Hydrochlroide

43. Erlotinib(osi-744)

44. Mls003899192

45. Mls004774139

46. Chembl1079742

47. Nsc 718781) Hcl

48. Dtxsid10171412

49. Ex-a064

50. Erlotinib Hydrochloride (tarceva)

51. Bcpp000238

52. Bcp02600

53. Erlotinib Hydrochloride [mi]

54. Ac-400

55. Erlotinib Hydrochloride [jan]

56. S1023

57. Akos015849087

58. Bcp9000658

59. Ccg-269002

60. Cs-0123

61. Erlotinib Hydrochloride [mart.]

62. Ks-1202

63. Pb30965

64. Sb16917

65. Erlotinib Hydrochloride [usp-rs]

66. Erlotinib Hydrochloride [who-dd]

67. Ro-50-8231

68. Be164421

69. Bp-30224

70. Hy-12008

71. (cp358774

72. Db-011534

73. Am20090622

74. Erlotinib Hydrochloride [orange Book]

75. Ft-0651479

76. Ec-000.2313

77. E-4007

78. 319e699

79. Q27124083

80. F0001-2385

81. Erlotinib Hydrochloride Is Known As A Egfr Kinase Inhibitor.

82. Erlotinib Hydrochloride,cp-358774, Osi-774, Nsc 718781

83. 6,7-bis-(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride

84. [6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl- Phenyl)amine Hydrochloride

85. N-(3-ethenylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Hydrochloride

86. N-(3-ethynylphenyl)-6,7-bis(1-methoxyethoxy)-4-quinazolinamine Hydrochloride

87. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Monohydrochloride

88. N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-quinazolin-4-amine Hydrochloride

2.4 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₄ClN₃O₄
Molecular Weight	429.9 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	11
Exact Mass	429.1455339 g/mol
Monoisotopic Mass	429.1455339 g/mol
Topological Polar Surface Area	74.7 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	525
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 4
Drug Name	Erlotinib hydrochloride
Drug Label	TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active Ingredient	Erlotinib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 150mg base; eq 25mg base
Market Status	Prescription
Company	Mylan Pharms

2 of 4
Drug Name	Tarceva
PubMed Health	Erlotinib (By mouth)
Drug Classes	Antineoplastic Agent, Immunological Agent
Drug Label	TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active Ingredient	Erlotinib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 150mg base; eq 25mg base
Market Status	Prescription
Company	Osi Pharms

3 of 4
Drug Name	Erlotinib hydrochloride
Drug Label	TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active Ingredient	Erlotinib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 150mg base; eq 25mg base
Market Status	Prescription
Company	Mylan Pharms

4 of 4
Drug Name	Tarceva
PubMed Health	Erlotinib (By mouth)
Drug Classes	Antineoplastic Agent, Immunological Agent
Drug Label	TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:Erloti...
Active Ingredient	Erlotinib hydrochloride
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 150mg base; eq 25mg base
Market Status	Prescription
Company	Osi Pharms

4.2 Drug Indication

* Non-small cell lung cancer (NSCLC):

Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.

Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.

No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.

* Pancreatic cancer :

Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer .

When prescribing Tarceva, factors associated with prolonged survival should be taken into account.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Protein Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]